LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY

Patients with HER2+ breast cancer have frequent LM. A multi center phase 1/2 study assessing safety and efficacy of IT T in LM patients was conducted. The primary endpoint in Phase 2 was response rate (RR). Complete response (CR) required cytologic CR (CCR) + radiographic CR (RCR) + stable clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumthekar, Priya, Lassman, Andrew B, Lin, Nancy, Grimm, Sean, Gradishar, William, Pentsova, Elena, Jeyapalan, Suriya, Groves, Morris, Melisko, Melissa, Raizer, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213435/
http://dx.doi.org/10.1093/noajnl/vdz014.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213435/
http://dx.doi.org/10.1093/noajnl/vdz014.025

Ejemplares similares